Chair Professor of Medicine, Head, Division of Infectious Diseases, Department of Medicine, Associate Dean, LKS Faculty of Medicine, University of Hong Kong
@PaulSaxMD Thx Paul. Major limitations of this study. The median age was 40 and half the subjects were of standard risks. Only 5% were above 65, whom Paxlovid is indicated and could make a difference. Also, we didn’t even know how many subjects have completed the 5 days treatment.